A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells. Song J, Yu J, Jeong LS, Lee SK, et al. Cancer Lett 2021;497:54-65.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Song J, Yu J, Jeong LS, Lee SK, et al. A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells. Cancer Lett 2021;497:54-65.
PMID: 33075425